TheraRadar
← Back
Data updated: Mar 29, 2026

MUNDIPHARMA

RespiratoryOncologyInfectious Disease
Pharma

MUNDIPHARMA is a pharmaceutical company focused on Respiratory, Oncology, Infectious Disease. Key products include REZZAYO.

2023
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

REZZAYO
rezafungin acetate
4 indications · 2023

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

REZZAYO 2025-12-10
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 43%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 2
Oncology 36%
0 drugs Phase 3: 1 Phase 1: 6
Infectious Disease 18%
0 drugs Phase 3: 1 Phase 1: 1
Dermatology 4%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Oncology, Dermatology
GSK big-pharma
Infectious Disease, Respiratory, Oncology
Sanofi big-pharma
Oncology, Infectious Disease, Respiratory
COSETTE other
Dermatology, Infectious Disease, Oncology